Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + cabozantinib vs cabozantinib in post-ICI advanced renal cell carcinoma
jRCT2080225357Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Atezolizumab + cabozantinib with Cabozantinib monotherapy (2 arms). Started Aug 2020; status: completed.
02
Drugs
atezolizumabcabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2080225357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225357.